{"entity":{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","aka":[],"tldr":"Indapta Therapeutics, of Houston, makes IDP-023, an off-the-shelf natural killer cell therapy from donor g-NK cells, a subset that lacks the FcR gamma chain, and tests it alongside antibody drugs in myeloma and non-Hodgkin lymphoma and in progressive multiple sclerosis. The FDA granted Fast Track status in 2024, and efficacy data are still early.","summary":"Indapta Therapeutics is developing IDP-023, a proprietary, off-the-shelf allogeneic FcR gamma-deficient natural killer (g-NK) cell therapy for cancer and autoimmune disease. According to release titles on the company site, the first patients were treated with IDP-023 in January 2024, the FDA granted Fast Track designation for non-Hodgkin lymphoma and myeloma in February 2024, the company received a $4.5 million CPRIT award in May 2024, an IND for progressive multiple sclerosis was cleared in August 2024, a clinical study collaboration with Sanofi in multiple myeloma was announced in December 2024, and clinical activity in relapsed or refractory multiple myeloma was presented in November 2025. SEC Form D filings list the company in Houston, Texas, with about $33.6 million of equity sold in early 2022 and about $50.8 million sold in an offering that began in September 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://indapta.com/"},{"label":"Form D, October 2025","url":"https://www.sec.gov/Archives/edgar/data/1910175/000191017525000003/primary_doc.xml"},{"label":"Form D, February 2022","url":"https://www.sec.gov/Archives/edgar/data/1910175/000191017522000001/primary_doc.xml"}],"tags":[],"related":[],"cancers":["multiple-myeloma","dlbcl"],"sections":["cell-therapy"],"technologies":["car-nk-macrophage","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06119685"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The user's hint says San Francisco; Form D filings give Houston, TX. Programme milestones are taken from press-release titles linked on the homepage (the Business Wire pages themselves returned 403). The g-NK product is not CAR-engineered; 'car-nk-macrophage' is the closest available id. The December 2024 $22.5 million financing release could not be fetched."],"hq":"Houston, TX","country":"US","companyType":"cell-therapy","website":"https://indapta.com/","stage":"startup","investors":[],"funding":[{"round":"Form D offering","year":2022,"amountUsd":33603097,"source":"https://www.sec.gov/Archives/edgar/data/1910175/000191017522000001/primary_doc.xml","note":"Amount sold at filing of a $67 million offering, first sale 28 January 2022"},{"round":"Form D offering","year":2025,"amountUsd":50800176,"source":"https://www.sec.gov/Archives/edgar/data/1910175/000191017525000003/primary_doc.xml","note":"Amount sold at filing of a $51.6 million offering, first sale 24 September 2025"}]},"route":"/companies/indapta-therapeutics/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"}],"trial":[{"id":"nct06119685","kind":"trial","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","route":"/trials/nct06119685/"}]}}